GlycoMimetics, Inc.

220 articles with GlycoMimetics, Inc.

• GlycoMimetics to Host 2018 Investor/Analyst Meeting at 60th ASH Annual Meeting on December 3, 2018

  11/29/2018

  GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it will host and webcast an investor/analyst meeting and update at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, on December 3 at 6 a.m. PT.

• Scott Jackson, Veteran Biopharmaceutical Executive, Joins GlycoMimetics Board of Directors

  11/28/2018

  Mr. Jackson served as Celator’s CEO and as a member of its Board of Directors from April 2008 until July 2016, when the company was acquired by Jazz Pharmaceuticals plc.

• GlycoMimetics Enrolls First Patient in Global Phase 3 Clinical Trial of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia

  11/19/2018

  Pivotal Trial to Evaluate Efficacy and Safety of Uproleselan in Patients with Advanced Acute Myeloid Leukemia (AML); Trial to Enroll 380 Patients at US and International Sites

• GlycoMimetics Reports Third Quarter 2018 Results and Highlights Recent Company Achievements

  11/2/2018

  Continued to select new clinical sites and ready previously-selected sites in the U.S., Europe, Canada and Australia for the company-sponsored Phase 3 pivotal trial in relapsed/refractory AML; study now open for enrollment

• GlycoMimetics to Present Analyses from Phase 1/2 AML Trial of Uproleselan at 60th ASH Meeting

  11/1/2018

  New and updated clinical outcomes data and subgroup analyses continue to demonstrate potential benefit of treatment with uproleselan when added to chemotherapy

• GlycoMimetics to Report Third Quarter 2018 Financial Results on November 2, 2018

  10/26/2018

  GlycoMimetics, Inc. announced today that it will host a conference call and webcast to provide a corporate update and report its third-quarter 2018 financial results on Friday, November 2, 2018, at 8:30 a.m. ET.

• GlycoMimetics to Present at Upcoming November 2018 Investor Conferences

  10/24/2018

  GlycoMimetics, Inc. today announced that Chief Executive Officer Rachel King will provide a company overview at two upcoming investor conferences, as follows

• GlycoMimetics Receives Japanese Patent For Uproleselan (GMI-1271)

  8/14/2018

  Issued patent expands global patent portfolio for GlycoMimetics’ late-stage drug candidate targeting treatment of broad spectrum of patients with acute myeloid leukemia

• GlycoMimetics Reports Second Quarter 2018 Results and Highlights Recent Company Achievements

  8/9/2018

  Announced a Cooperative Research and Development Agreement (CRADA) to collaborate with the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology to fund a planned pivotal Phase 3 trial to evaluate uproleselan (GMI-1271) in older, newly diagnosed acute myeloid leukemia (AML) patients eligible for intensive chemotherapy

• GlycoMimetics to Report Second Quarter 2018 Financial Results on August 9, 2018

  8/2/2018

  GlycoMimetics, Inc. announced that it will report its second quarter 2018 financial results on Thursday August 9, 2018, and will host a conference call and webcast on Friday, August 10, 2018, at 8:30 a.m. ET.

• GlycoMimetics to Present at Jefferies 2018 Global Healthcare Conference

  6/1/2018

  GlycoMimetics, Inc. announced that Chief Executive Officer Rachel King will provide a company overview at the Jefferies Annual Health Care Conference.

• GlycoMimetics Announces NCI-Sponsored Pivotal Trial of GMI-1271 in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy

  5/30/2018

  Third of three planned trials positions GlycoMimetics to address unmet needs across the AML spectrum

• GlycoMimetics Reports First Quarter 2018 Results

  5/3/2018

  GlycoMimetics, Inc. reported its financial results for the first quarter ended March 31, 2018 and highlighted recent company achievements.

• GlycoMimetics to Report First Quarter 2018 Financial Results on May 3, 2018

  4/26/2018

  GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its first quarter 2018 financial results on Thursday, May 3, 2018, at 8:30 a.m. ET.

• GlycoMimetics Announces Pricing of Public Offering of Common Stock At $17 Per Share

  3/21/2018

  GlycoMimetics, Inc. announced the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a price to the public of $17.00 per share.

• GlycoMimetics Announces Proposed Public Offering 4,500,000 Shares of Common Stock

  3/19/2018

  GlycoMimetics, Inc. announced that it intends to offer and sell, subject to market conditions, 4,500,000 shares of its common stock in an underwritten public offering.

• GlycoMimetics to Present New Preclinical Data for GMI-1271 and GMI-1359 at AACR Annual Meeting 2018

  3/14/2018

  GlycoMimetics, Inc. announced that preclinical research suggesting the potential of two of its drug candidates, GMI-1271 and GMI-1359, as treatments for acute myeloid leukemia (AML), metastasis in osteosarcoma and other cancers will be shared via poster presentations at the AACR Annual Meeting 2018 in Chicago.

• GlycoMimetics to Present at Four Investor Conferences This Month

  3/7/2018

  GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will present at four investor conferences during the month of March

• GlycoMimetics Reports Fourth Quarter and Year-End 2017 Results

  3/6/2018

  The Phase 3 trial of rivipansel remains on track for completion during the second half of 2018.

• GlycoMimetics Announces Design of Phase 3 Clinical Trial for GMI-1271 in Relapsed/Refractory AML

  3/5/2018

  GlycoMimetics, Inc. (NASDAQ: GLYC) announced today its design for a randomized, double-blind, placebo-controlled Phase 3 clinical trial to evaluate GMI-1271 in combination with MEC (Mitoxantrone, etoposide and Ara-C) or in combination with FAI (fludarabine, cytosine arabinoside and idarubicin) in individuals with relapsed/refractory acute myeloid leukemia (AML).